Hydromorphone

Identification

Name

Hydromorphone

Accession Number

DB00327  (APRD01021)

Type

Small Molecule

Groups

Approved, Illicit

Description

An opioid analgesic derived from morphine and used mainly as an analgesic. It has a shorter duration of action and is more potent than morphine. [PubChem]

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00327 (Hydromorphone)

×

Close

Synonyms

• (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one
• 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one
• 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone
• 6-Deoxy-7,8-dihydro-6-oxomorphine
• 7,8-Dihydromorphinone
• Dihydromorfinon
• Dihydromorphinone
• Dimorphone
• Hidromorfona
• Hydromorfona
• Hydromorphone
• Hydromorphonum
• Idromorfone

External IDs

IDS-NH-004 / N02AA03 / NSC-19046

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Hydromorphone Hydrochloride	L960UP2KRW	71-68-1	XHILEZUETWRSHC-NRGUFEMZSA-N
Hydromorphone sulfate	75Y990NH3Z	25333-57-7	JBBINZRUTLUBFR-NRGUFEMZSA-N

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Dilaudid	Tablet	4 mg/1	Oral	Mckesson Rxpak Inc	1956-01-01	Not applicable
Dilaudid	Tablet	4 mg/1	Oral	Cardinal Health	1926-01-01	Not applicable
Dilaudid	Tablet	4 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	1956-01-01	2016-12-21
Dilaudid	Tablet	4 mg/1	Oral	Rhodes Pharmaceuticals, L.P.	2017-05-15	Not applicable
Dilaudid	Injection, solution	2 mg/mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	2016-12-16	Not applicable
Dilaudid	Injection, solution	2 mg/mL	Intramuscular; Intravenous; Subcutaneous	Purdue Pharma LP	1926-01-01	Not applicable
Dilaudid	Liquid	2 mg	Intramuscular; Intravenous; Subcutaneous	Purdue Pharma	1984-12-31	Not applicable
Dilaudid	Tablet	2 mg/1	Oral	Purdue Pharma LP	1956-01-01	Not applicable
Dilaudid	Solution	5 mg/5mL	Oral	Rhodes Pharmaceuticals, L.P.	2017-05-15	Not applicable
Dilaudid	Powder, for solution	250 mg	Intramuscular; Intravenous; Subcutaneous	Purdue Pharma	1994-12-31	2013-06-07

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-hydromorphone	Tablet	4 mg	Oral	Apotex Corporation	2012-12-18	Not applicable
Apo-hydromorphone	Tablet	2 mg	Oral	Apotex Corporation	2012-12-18	Not applicable
Apo-hydromorphone	Tablet	8 mg	Oral	Apotex Corporation	2012-12-18	Not applicable
Apo-hydromorphone	Tablet	1 mg	Oral	Apotex Corporation	2012-12-18	Not applicable
Bar-hydromorphone HCl	Capsule, extended release	30 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-hydromorphone HCl	Capsule, extended release	12 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-hydromorphone HCl	Capsule, extended release	4.5 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-hydromorphone HCl	Capsule, extended release	24 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-hydromorphone HCl	Capsule, extended release	9 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-hydromorphone HCl	Capsule, extended release	3 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Hydromorphone HCl	Hydromorphone Hydrochloride (.2 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2010-08-23	2017-12-22
Hydromorphone HCl	Hydromorphone Hydrochloride (2 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2014-08-13	Not applicable
Hydromorphone HCl	Hydromorphone Hydrochloride (1 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2011-06-30	2017-12-22
Hydromorphone HCl	Hydromorphone Hydrochloride (.4 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2014-08-13	Not applicable
Hydromorphone HCl	Hydromorphone Hydrochloride (.5 mg/mL)	Injection, solution	Intramuscular; Intravenous; Subcutaneous	Cantrell Drug Company	2012-01-18	Not applicable
Hydromorphone HCl	Hydromorphone Hydrochloride (.1 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2014-08-21	Not applicable
Hydromorphone HCl	Hydromorphone Hydrochloride (10 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2014-08-13	Not applicable
Hydromorphone Hydrochloride	Hydromorphone Hydrochloride (2 mg/mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West Ward Pharmaceutical	1972-01-01	Not applicable
Hydromorphone Hydrochloride	Hydromorphone Hydrochloride (2 mg/mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West Ward Pharmaceutical	1972-01-01	Not applicable
Hydromorphone Hydrochloride	Hydromorphone Hydrochloride (3 mg/1)	Suppository	Rectal	Paddock Laboratories, Inc.	1996-01-31	Not applicable

International/Other Brands

Palladone

Categories

• Alkaloids
• Analgesics
• Analgesics, Opioid
• Central Nervous System Agents
• Central Nervous System Depressants
• Cytochrome P-450 CYP2C9 Substrates
• Cytochrome P-450 CYP2D6 Substrates
• Cytochrome P-450 CYP3A4 Substrates
• Morphinans
• Morphine Derivatives
• Narcotics
• Natural Opium Alkaloids
• Nervous System
• Opiate Agonists
• Opiate Alkaloids
• Opioid Agonist
• Peripheral Nervous System Agents
• Phenanthrenes
• Sensory System Agents

UNII

Q812464R06

CAS number

466-99-9

Weight

Average: 285.3377
Monoisotopic: 285.136493479

Chemical Formula

C₁₇H₁₉NO₃

InChI Key

WVLOADHCBXTIJK-YNHQPCIGSA-N

InChI

InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

IUPAC Name

(1S,5R,13R,17R)-10-hydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one

SMILES

[H][[email protected]@]12OC3=C(O)C=CC4=C3[[email protected]@]11CCN(C)[[email protected]]([H])(C4)[[email protected]]1([H])CCC2=O

Pharmacology

Indication

For the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns.

Structured Indications

• Pain
• Pain, Neuropathic

Pharmacodynamics

Hydromorphone is a hydrogenated ketone derivative of morphine that acts as a narcotic analgesic. It has a shorter duration of action than morphine. Hydromorphone is approximately 8 times more potent on a milligram basis than morphine. In addition, hydromorphone is better absorbed orally than is morphine. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Hydromorphone appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.

Mechanism of action

Hydromorphone is a narcotic analgesic; its principal therapeutic effect is relief of pain. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Hydromorphone also binds with kappa-receptors which are thought to mediate spinal analgesia, miosis and sedation.

Target	Actions	Organism
AMu-type opioid receptor	agonist	Human
ADelta-type opioid receptor	partial agonist	Human
AKappa-type opioid receptor	agonist	Human

Absorption

Better absorbed orally than morphine

Volume of distribution

Not Available

Protein binding

20%

Metabolism

Primarily hepatic. After absorption hydromorphone is metabolized by the liver to the glucuronide conjugate which is then excreted in the urine. Hydromorphone is metabolized to the major metabolites hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide.

• Hydromorphone
  Dihydromorphine
  • Dihydromorphine
    Dihydromorphine-3-glucuronide
• Hydromorphone
  Dihydroisomorphine
• Hydromorphone
  Norhydromorphone
• Hydromorphone
  Hydromorphone 3-beta-O-glucuronide
• Hydromorphone
  Dihydroisomorphine-6-glucuronide
• Hydromorphone
  Hydromorphone-3-glucoside
• Hydromorphone
  Hydromorphone-3-glucuronide
• Hydromorphone
  Hydromorphone-3-sulphate

Route of elimination

Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.

Half life

2.6 hours (oral); 18.6 hours for sustained release Palladone

Clearance

• 1.96 L/min

Toxicity

Hydromorphone is a schedule II narcotic which can lead to physical dependence or addiction. High doses lead to respiratory depression, nausea, and vomiting. Overdoses lead to extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Hydromorphone Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydromorphone.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Hydromorphone.	Experimental
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydromorphone.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydromorphone.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.	Experimental
Abiraterone	The serum concentration of Hydromorphone can be increased when it is combined with Abiraterone.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Aceprometazine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acetazolamide.	Approved, Vet Approved
Aclidinium	The risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Agomelatine.	Approved, Investigational
Alaproclate	Hydromorphone may increase the serotonergic activities of Alaproclate.	Experimental
Alcuronium	The risk or severity of adverse effects can be increased when Alcuronium is combined with Hydromorphone.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfentanil.	Approved, Illicit
Alimemazine	Alimemazine may increase the hypotensive activities of Hydromorphone.	Approved, Vet Approved
Allopregnanolone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Allopregnanolone.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam.	Approved, Illicit, Investigational
Alvimopan	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alvimopan.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amiloride.	Approved
Amiodarone	The metabolism of Hydromorphone can be decreased when combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amitriptyline.	Approved
Ammonium chloride	Ammonium chloride may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.	Approved, Investigational, Vet Approved
Amobarbital	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amperozide.	Experimental
Amphetamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amphetamine.	Approved, Illicit, Investigational
Anisotropine Methylbromide	The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydromorphone.	Approved
Apalutamide	The serum concentration of Hydromorphone can be decreased when it is combined with Apalutamide.	Approved, Investigational
Aprepitant	The serum concentration of Hydromorphone can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.	Approved, Investigational
Artemether	The metabolism of Hydromorphone can be decreased when combined with Artemether.	Approved
Articaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Asenapine.	Approved
Atazanavir	The metabolism of Hydromorphone can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	The metabolism of Hydromorphone can be decreased when combined with Atomoxetine.	Approved
Atracurium	The risk or severity of adverse effects can be increased when Atracurium is combined with Hydromorphone.	Approved, Experimental, Investigational
Atracurium besylate	The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone.	Approved
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Hydromorphone.	Approved, Vet Approved
Azaperone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Azaperone.	Investigational, Vet Approved
Azelastine	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azosemide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Azosemide.	Investigational
Baclofen	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.	Illicit
Benactyzine	The risk or severity of adverse effects can be increased when Benactyzine is combined with Hydromorphone.	Withdrawn
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bendroflumethiazide.	Approved
Benmoxin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benmoxin.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benperidol.	Approved, Investigational
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Hydromorphone.	Approved
Benzocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzocaine.	Approved, Investigational
Benzphetamine	Benzphetamine may increase the analgesic activities of Hydromorphone.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzyl alcohol.	Approved
Betaxolol	The metabolism of Hydromorphone can be decreased when combined with Betaxolol.	Approved, Investigational
Biperiden	The risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone.	Approved, Investigational
BL-1020	BL-1020 may increase the hypotensive activities of Hydromorphone.	Investigational
Boceprevir	The metabolism of Hydromorphone can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bornaprine	The risk or severity of adverse effects can be increased when Bornaprine is combined with Hydromorphone.	Experimental
Bortezomib	The metabolism of Hydromorphone can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Hydromorphone can be decreased when it is combined with Bosentan.	Approved, Investigational
Brexpiprazole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved
Brofaromine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brofaromine.	Experimental
Bromazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromisoval.	Experimental
Bromperidol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brotizolam.	Approved, Investigational, Withdrawn
Bumetanide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bupivacaine.	Approved, Investigational
Buprenorphine	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Hydromorphone can be decreased when combined with Bupropion.	Approved
Buspirone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butamben.	Approved, Withdrawn
Butethal	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butethal.	Approved, Illicit
Butorphanol	Butorphanol may decrease the analgesic activities of Hydromorphone.	Approved, Illicit, Vet Approved
Butylscopolamine	The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Hydromorphone.	Approved, Investigational, Vet Approved
Canertinib	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Canertinib.	Investigational
Canrenoic acid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenoic acid.	Approved, Withdrawn
Canrenone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenone.	Investigational
Capecitabine	The metabolism of Hydromorphone can be decreased when combined with Capecitabine.	Approved, Investigational
Carbamazepine	The metabolism of Hydromorphone can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Caroxazone.	Withdrawn
Celecoxib	The metabolism of Hydromorphone can be decreased when combined with Celecoxib.	Approved, Investigational
Ceritinib	The serum concentration of Hydromorphone can be increased when it is combined with Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlordiazepoxide.	Approved, Illicit, Investigational
Chlormezanone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlormezanone.	Approved, Investigational, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine.	Approved
Chloroquine	The metabolism of Hydromorphone can be decreased when combined with Chloroquine.	Approved, Investigational, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine.	Approved
Chlorphenoxamine	The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone.	Withdrawn
Chlorphentermine	Chlorphentermine may increase the analgesic activities of Hydromorphone.	Illicit, Withdrawn
Chlorproethazine	Chlorproethazine may increase the hypotensive activities of Hydromorphone.	Experimental
Chlorpromazine	The metabolism of Hydromorphone can be decreased when combined with Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorthalidone.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone.	Approved
Cholecalciferol	The metabolism of Hydromorphone can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cicletanine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cicletanine.	Investigational
Cimetidine	The metabolism of Hydromorphone can be decreased when combined with Cimetidine.	Approved, Investigational
Cinacalcet	The metabolism of Hydromorphone can be decreased when combined with Cinacalcet.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine.	Approved, Vet Approved
Citalopram	The metabolism of Hydromorphone can be decreased when combined with Citalopram.	Approved
Clarithromycin	The metabolism of Hydromorphone can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Hydromorphone can be decreased when combined with Clemastine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clidinium.	Approved
Clobazam	The metabolism of Hydromorphone can be decreased when combined with Clobazam.	Approved, Illicit
Clofenamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clofenamide.	Experimental
clomethiazole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with clomethiazole.	Investigational
Clomipramine	The metabolism of Hydromorphone can be decreased when combined with Clomipramine.	Approved, Investigational, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine.	Approved
Clopamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clopamide.	Experimental
Clopenthixol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clopenthixol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate.	Approved, Illicit
Clorexolone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorexolone.	Experimental
Clothiapine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clothiapine.	Experimental
Clotrimazole	The metabolism of Hydromorphone can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Hydromorphone can be decreased when combined with Clozapine.	Approved
Cobicistat	The serum concentration of Hydromorphone can be increased when it is combined with Cobicistat.	Approved
Cocaine	The metabolism of Hydromorphone can be decreased when combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Hydromorphone.	Approved, Illicit
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Hydromorphone.	Approved, Investigational
Crisaborole	The metabolism of Hydromorphone can be decreased when combined with Crisaborole.	Approved, Investigational
Crizotinib	The metabolism of Hydromorphone can be decreased when combined with Crizotinib.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.	Approved
Cyclopenthiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclopenthiazide.	Experimental
Cyclopentolate	The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydromorphone.	Approved
Cyclopropane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclopropane.	Experimental
Cyclosporine	The metabolism of Hydromorphone can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclothiazide.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyproheptadine.	Approved
Dabrafenib	The serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dantrolene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.	Approved, Investigational
Dapiprazole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dapiprazole.	Approved
Dapoxetine	Hydromorphone may increase the serotonergic activities of Dapoxetine.	Investigational
Darifenacin	The metabolism of Hydromorphone can be decreased when combined with Darifenacin.	Approved, Investigational
Darunavir	The serum concentration of Hydromorphone can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Hydromorphone can be increased when it is combined with Dasatinib.	Approved, Investigational
Deferasirox	The serum concentration of Hydromorphone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Hydromorphone can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane.	Approved
Desipramine	The metabolism of Hydromorphone can be decreased when combined with Desipramine.	Approved, Investigational
Desloratadine	The risk or severity of adverse effects can be increased when Desloratadine is combined with Hydromorphone.	Approved, Investigational
Desmopressin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.	Approved
Desvenlafaxine	Hydromorphone may increase the serotonergic activities of Desvenlafaxine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Detomidine.	Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.	Approved
Dexetimide	The risk or severity of adverse effects can be increased when Dexetimide is combined with Hydromorphone.	Withdrawn
Dexmedetomidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	Dextroamphetamine may increase the analgesic activities of Hydromorphone.	Approved, Illicit
Dextromoramide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dezocine.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diazepam.	Approved, Illicit, Investigational, Vet Approved
Dicyclomine	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.	Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diethyl ether.	Experimental
Diethylpropion	Diethylpropion may increase the analgesic activities of Hydromorphone.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.	Approved, Illicit
Dihydroergotamine	The metabolism of Hydromorphone can be decreased when combined with Dihydroergotamine.	Approved, Investigational
Dihydroetorphine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The metabolism of Hydromorphone can be decreased when combined with Diltiazem.	Approved, Investigational
Dimenhydrinate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.	Approved
Diphenhydramine	The metabolism of Hydromorphone can be decreased when combined with Diphenhydramine.	Approved, Investigational
Diphenoxylate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate.	Approved, Illicit
Dixyrazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dixyrazine.	Experimental
Doramectin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Doramectin.	Vet Approved
Dosulepin	The metabolism of Hydromorphone can be decreased when combined with Dosulepin.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin.	Approved, Investigational
Doxycycline	The metabolism of Hydromorphone can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Hydromorphone is combined with DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved, Illicit
Dronedarone	The metabolism of Hydromorphone can be decreased when combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved, Vet Approved
Drospirenone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Drospirenone.	Approved
Drotebanol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The metabolism of Hydromorphone can be decreased when combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecopipam.	Investigational
Efavirenz	The metabolism of Hydromorphone can be decreased when combined with Efavirenz.	Approved, Investigational
Efonidipine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Efonidipine.	Approved, Investigational
Eliglustat	The metabolism of Hydromorphone can be decreased when combined with Eliglustat.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eltanolone.	Investigational
Eluxadoline	Hydromorphone may increase the constipating activities of Eluxadoline.	Approved, Investigational
Emepronium	The risk or severity of adverse effects can be increased when Emepronium is combined with Hydromorphone.	Experimental
Enflurane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Enflurane.	Approved, Investigational, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.	Approved
Epitizide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Epitizide.	Experimental
Eplerenone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eplerenone.	Approved
Erythromycin	The metabolism of Hydromorphone can be decreased when combined with Erythromycin.	Approved, Investigational, Vet Approved
Escitalopram	Hydromorphone may increase the serotonergic activities of Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Estazolam.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eszopiclone.	Approved, Investigational
Etacrynic acid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.	Approved, Investigational
Etanautine	The risk or severity of adverse effects can be increased when Etanautine is combined with Hydromorphone.	Experimental
Ethanol	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethopropazine	The risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydromorphone.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.	Approved
Ethoxzolamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethoxzolamide.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etifoxine.	Investigational, Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etomidate.	Approved
Etoperidone	Hydromorphone may increase the serotonergic activities of Etoperidone.	Withdrawn
Etorphine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The metabolism of Hydromorphone can be decreased when combined with Etravirine.	Approved
Etybenzatropine	The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Hydromorphone.	Experimental
Ezogabine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ezogabine.	Approved, Investigational
Felbamate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenquizone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fenquizone.	Experimental
Fentanyl	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.	Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fexofenadine.	Approved, Investigational
Flibanserin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.	Approved, Investigational
Floxuridine	The metabolism of Hydromorphone can be decreased when combined with Floxuridine.	Approved
Fluanisone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluanisone.	Experimental
Fluconazole	The metabolism of Hydromorphone can be decreased when combined with Fluconazole.	Approved, Investigational
Fludiazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunitrazepam.	Approved, Illicit
Fluorouracil	The metabolism of Hydromorphone can be decreased when combined with Fluorouracil.	Approved
Fluoxetine	The metabolism of Hydromorphone can be decreased when combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam.	Approved, Illicit, Investigational
Fluspirilene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluticasone propionate.	Approved
Fluvastatin	The metabolism of Hydromorphone can be decreased when combined with Fluvastatin.	Approved
Fluvoxamine	The metabolism of Hydromorphone can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Hydromorphone can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Hydromorphone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Hydromorphone can be increased when combined with Fosphenytoin.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fospropofol.	Approved, Illicit, Investigational
Furazolidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Furazolidone.	Approved, Investigational, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Hydromorphone can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin Enacarbil.	Approved, Investigational
Gallamine	The risk or severity of adverse effects can be increased when Gallamine is combined with Hydromorphone.	Experimental
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydromorphone.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit, Investigational
Gemfibrozil	The metabolism of Hydromorphone can be decreased when combined with Gemfibrozil.	Approved
Gepefrine	Gepefrine may increase the analgesic activities of Hydromorphone.	Experimental
Gepirone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Glutethimide.	Approved, Illicit
Glycopyrronium	The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydromorphone.	Approved, Investigational, Vet Approved
Guanfacine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The metabolism of Hydromorphone can be decreased when combined with Haloperidol.	Approved
Halothane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.	Approved, Vet Approved
Harmaline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Harmaline.	Experimental
Heroin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Heroin.	Approved, Illicit, Investigational
Hexamethonium	The risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydromorphone.	Experimental
Hexobarbital	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hexobarbital.	Approved
Homatropine	The risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone.	Approved
Hydracarbazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydracarbazine.	Experimental
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroflumethiazide.	Approved, Investigational
Hydroxyamphetamine	Hydroxyamphetamine may increase the analgesic activities of Hydromorphone.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydromorphone.	Approved
Ibopamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ibopamine.	Experimental
Idelalisib	The metabolism of Hydromorphone can be decreased when combined with Idelalisib.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.	Approved
Imatinib	The metabolism of Hydromorphone can be decreased when combined with Imatinib.	Approved
Imipramine	The metabolism of Hydromorphone can be decreased when combined with Imipramine.	Approved
Indalpine	Hydromorphone may increase the serotonergic activities of Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.	Approved
Indinavir	The metabolism of Hydromorphone can be decreased when combined with Indinavir.	Approved
Indiplon	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Indiplon.	Investigational
Iofetamine I-123	Iofetamine I-123 may increase the analgesic activities of Hydromorphone.	Approved
Ipratropium bromide	The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.	Approved
Iproclozide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iproclozide.	Withdrawn
Iproniazid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iproniazid.	Withdrawn
Irbesartan	The metabolism of Hydromorphone can be decreased when combined with Irbesartan.	Approved, Investigational
Isavuconazole	The serum concentration of Hydromorphone can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Hydromorphone can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Isoflurane.	Approved, Vet Approved
Isoniazid	The metabolism of Hydromorphone can be decreased when combined with Isoniazid.	Approved, Investigational
Isosorbide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Isosorbide.	Approved, Investigational
Isradipine	The metabolism of Hydromorphone can be decreased when combined with Isradipine.	Approved, Investigational
Itraconazole	The metabolism of Hydromorphone can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Hydromorphone can be increased when it is combined with Ivacaftor.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone.	Approved, Investigational
Ketoconazole	The metabolism of Hydromorphone can be decreased when combined with Ketoconazole.	Approved, Investigational
Lamotrigine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine.	Approved, Investigational
Leflunomide	The metabolism of Hydromorphone can be decreased when combined with Leflunomide.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levobupivacaine.	Approved, Investigational
Levocabastine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levomethadyl Acetate.	Approved, Investigational
Levomilnacipran	Hydromorphone may increase the serotonergic activities of Levomilnacipran.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lidocaine.	Approved, Vet Approved
Lisdexamfetamine	Lisdexamfetamine may increase the analgesic activities of Hydromorphone.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.	Approved
Lobeglitazone	The metabolism of Hydromorphone can be decreased when combined with Lobeglitazone.	Approved, Investigational
Lofentanil	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lofentanil.	Illicit
Lopinavir	The metabolism of Hydromorphone can be decreased when combined with Lopinavir.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loratadine.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Hydromorphone.	Approved
Lorcaserin	The metabolism of Hydromorphone can be decreased when combined with Lorcaserin.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lormetazepam.	Approved
Lorpiprazole	The serum concentration of Hydromorphone can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The metabolism of Hydromorphone can be decreased when combined with Losartan.	Approved
Lovastatin	The metabolism of Hydromorphone can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.	Approved
Luliconazole	The serum concentration of Hydromorphone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Hydromorphone can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The metabolism of Hydromorphone can be decreased when combined with Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.	Approved, Investigational
Magnesium sulfate	The therapeutic efficacy of Hydromorphone can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Manidipine	The metabolism of Hydromorphone can be decreased when combined with Manidipine.	Approved, Investigational
Mannitol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.	Approved, Investigational
Mazaticol	The risk or severity of adverse effects can be increased when Mazaticol is combined with Hydromorphone.	Experimental
Mebanazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebanazine.	Withdrawn
Mebicar	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebicar.	Experimental
Mebutizide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebutizide.	Experimental
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meclizine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Medetomidine.	Vet Approved
Mefruside	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mefruside.	Experimental
Melatonin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melperone.	Approved, Investigational
Mephedrone	Mephedrone may increase the analgesic activities of Hydromorphone.	Investigational
Mephentermine	Mephentermine may increase the analgesic activities of Hydromorphone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meptazinol.	Experimental
Mersalyl	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mersalyl.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.	Approved
Methadone	The metabolism of Hydromorphone can be decreased when combined with Methadone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	Methamphetamine may increase the analgesic activities of Hydromorphone.	Approved, Illicit
Methantheline	The risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone.	Approved, Investigational
Methapyrilene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methaqualone.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methazolamide.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital.	Approved
Methotrimeprazine	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane.	Approved, Investigational, Vet Approved
Methoxyphenamine	Methoxyphenamine may increase the analgesic activities of Hydromorphone.	Experimental
Methscopolamine	The risk or severity of adverse effects can be increased when Methscopolamine is combined with Hydromorphone.	Approved
Methsuximide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylecgonine.	Experimental
Methylene blue	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylene blue.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylphenobarbital.	Approved
Methylscopolamine bromide	The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Hydromorphone.	Approved
Meticrane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meticrane.	Experimental
Metixene	The risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.	Approved
Metoprolol	The metabolism of Hydromorphone can be decreased when combined with Metoprolol.	Approved, Investigational
Metyrosine	Hydromorphone may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.	Approved, Illicit
Midomafetamine	Midomafetamine may increase the analgesic activities of Hydromorphone.	Experimental, Illicit, Investigational
Midostaurin	The metabolism of Hydromorphone can be decreased when combined with Midostaurin.	Approved, Investigational
Mifepristone	The serum concentration of Hydromorphone can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	Hydromorphone may increase the serotonergic activities of Milnacipran.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Minaprine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved, Investigational
Mirabegron	The metabolism of Hydromorphone can be decreased when combined with Mirabegron.	Approved
Mirtazapine	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Hydromorphone can be decreased when it is combined with Mitotane.	Approved
MMDA	MMDA may increase the analgesic activities of Hydromorphone.	Experimental, Illicit
Moclobemide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Moclobemide.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone.	Approved
Moricizine	Moricizine may increase the hypotensive activities of Hydromorphone.	Approved, Investigational, Withdrawn
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.	Approved, Investigational
Muzolimine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Muzolimine.	Experimental
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved, Investigational
Nalbuphine	Nalbuphine may decrease the analgesic activities of Hydromorphone.	Approved
Naltrexone	The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naltrexone.	Approved, Investigational, Vet Approved
Nefazodone	The metabolism of Hydromorphone can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Hydromorphone can be decreased when combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Hydromorphone can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Hydromorphone can be increased when combined with Nevirapine.	Approved
Nialamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nialamide.	Withdrawn
Nicardipine	The metabolism of Hydromorphone can be decreased when combined with Nicardipine.	Approved, Investigational
Nilotinib	The metabolism of Hydromorphone can be decreased when combined with Nilotinib.	Approved, Investigational
Nitrazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Norflurane.	Approved, Investigational
Normethadone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nortriptyline.	Approved
Octamoxin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Octamoxin.	Withdrawn
Olanzapine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine.	Approved, Investigational
Olaparib	The metabolism of Hydromorphone can be decreased when combined with Olaparib.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine.	Approved
Omeprazole	The metabolism of Hydromorphone can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Opium.	Approved, Illicit
Orphenadrine	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Hydromorphone can be increased when it is combined with Osimertinib.	Approved
Otilonium	The risk or severity of adverse effects can be increased when Otilonium is combined with Hydromorphone.	Experimental, Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxethazaine.	Approved, Investigational
Oxitropium	The risk or severity of adverse effects can be increased when Oxitropium is combined with Hydromorphone.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxybuprocaine.	Approved, Investigational
Oxybutynin	The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydromorphone.	Approved
Palbociclib	The serum concentration of Hydromorphone can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.	Approved
Pamabrom	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pamabrom.	Approved
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.	Approved
Panobinostat	The serum concentration of Hydromorphone can be increased when it is combined with Panobinostat.	Approved, Investigational
Paraldehyde	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Pargyline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pargyline.	Approved
Paroxetine	The metabolism of Hydromorphone can be decreased when combined with Paroxetine.	Approved, Investigational
Peginterferon alfa-2b	The serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Pegvisomant	The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.	Approved
Penfluridol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Penfluridol.	Experimental
Pentazocine	Pentazocine may decrease the analgesic activities of Hydromorphone.	Approved, Vet Approved
Pentobarbital	The metabolism of Hydromorphone can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentolinium	The risk or severity of adverse effects can be increased when Pentolinium is combined with Hydromorphone.	Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved
Perazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Perazine.	Approved, Investigational
Perospirone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pethidine.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenazocine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenelzine.	Approved
Phenglutarimide	The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hydromorphone.	Experimental
Phenibut	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenibut.	Experimental
Pheniprazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pheniprazine.	Withdrawn
Phenobarbital	The metabolism of Hydromorphone can be increased when combined with Phenobarbital.	Approved, Investigational
Phenoperidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoperidine.	Experimental
Phenoxyethanol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoxyethanol.	Approved
Phenoxypropazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoxypropazine.	Withdrawn
Phentermine	Phentermine may increase the analgesic activities of Hydromorphone.	Approved, Illicit
Phenytoin	The metabolism of Hydromorphone can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone.	Approved, Investigational
Pipecuronium	The risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipotiazine.	Approved, Investigational
Pirenzepine	The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.	Approved
Piretanide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Piritramide.	Approved, Investigational
Pirlindole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pirlindole.	Approved
Pitolisant	The serum concentration of Hydromorphone can be decreased when it is combined with Pitolisant.	Approved, Investigational
Pivhydrazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pivhydrazine.	Withdrawn
Pizotifen	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pizotifen.	Approved
Polythiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.	Approved
Posaconazole	The metabolism of Hydromorphone can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Potassium	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium.	Approved, Investigational
Potassium Citrate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.	Approved, Investigational, Vet Approved
Pramipexole	Hydromorphone may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam.	Approved, Illicit
Pregabalin	The therapeutic efficacy of Hydromorphone can be increased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prilocaine.	Approved
Primidone	The metabolism of Hydromorphone can be increased when combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Procarbazine.	Approved, Investigational
Prochlorperazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine.	Approved, Vet Approved
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone.	Approved
Promazine	The metabolism of Hydromorphone can be decreased when combined with Promazine.	Approved, Vet Approved
Promethazine	Promethazine may increase the hypotensive activities of Hydromorphone.	Approved, Investigational
Propanidid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propanidid.	Experimental
Propantheline	The risk or severity of adverse effects can be increased when Propantheline is combined with Hydromorphone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Proparacaine.	Approved, Vet Approved
Propericiazine	Propericiazine may increase the hypotensive activities of Hydromorphone.	Approved, Investigational
Propiopromazine	Propiopromazine may increase the hypotensive activities of Hydromorphone.	Vet Approved
Propiverine	The risk or severity of adverse effects can be increased when Propiverine is combined with Hydromorphone.	Approved, Investigational
Propofol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Hydromorphone is combined with PSD502.	Investigational
Pseudoephedrine	Pseudoephedrine may increase the analgesic activities of Hydromorphone.	Approved
Pyrimethamine	The metabolism of Hydromorphone can be decreased when combined with Pyrimethamine.	Approved, Investigational, Vet Approved
Quazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.	Approved
Quinethazone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinethazone.	Approved
Quinidine	The metabolism of Hydromorphone can be decreased when combined with Quinidine.	Approved, Investigational
Quinine	The metabolism of Hydromorphone can be decreased when combined with Quinine.	Approved
Quinisocaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinisocaine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon.	Approved, Investigational
Ramosetron	Hydromorphone may increase the constipating activities of Ramosetron.	Approved, Investigational
Ranolazine	The metabolism of Hydromorphone can be decreased when combined with Ranolazine.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Rasagiline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone.	Approved, Investigational
Rifabutin	The metabolism of Hydromorphone can be increased when combined with Rifabutin.	Approved, Investigational
Rifampicin	The metabolism of Hydromorphone can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Hydromorphone can be increased when combined with Rifapentine.	Approved, Investigational
Rilpivirine	The serum concentration of Hydromorphone can be decreased when it is combined with Rilpivirine.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ritanserin.	Investigational
Ritobegron	Ritobegron may increase the analgesic activities of Hydromorphone.	Investigational
Ritonavir	The metabolism of Hydromorphone can be decreased when combined with Ritonavir.	Approved, Investigational
Rolapitant	The metabolism of Hydromorphone can be decreased when combined with Rolapitant.	Approved, Investigational
Rolofylline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Rolofylline.	Investigational
Romifidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Romifidine.	Vet Approved
Ropinirole	Hydromorphone may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ropivacaine.	Approved
Rotigotine	Hydromorphone may increase the sedative activities of Rotigotine.	Approved
Rucaparib	The metabolism of Hydromorphone can be decreased when combined with Rucaparib.	Approved, Investigational
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Hydromorphone.	Approved
Safrazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Safrazine.	Withdrawn
Saquinavir	The metabolism of Hydromorphone can be decreased when combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Sarilumab.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.	Approved, Investigational
Secobarbital	The metabolism of Hydromorphone can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Selegiline.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	The metabolism of Hydromorphone can be decreased when combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The metabolism of Hydromorphone can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Hydromorphone can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Hydromorphone can be increased when it is combined with Simeprevir.	Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved
Solifenacin	The risk or severity of adverse effects can be increased when Solifenacin is combined with Hydromorphone.	Approved
Sorafenib	The metabolism of Hydromorphone can be decreased when combined with Sorafenib.	Approved, Investigational
Spiradoline	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Spiradoline.	Investigational
Spironolactone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Hydromorphone can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Hydromorphone can be increased when it is combined with Stiripentol.	Approved
Succinylcholine	Succinylcholine may increase the bradycardic activities of Hydromorphone.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.	Approved, Investigational
Sulfadiazine	The metabolism of Hydromorphone can be decreased when combined with Sulfadiazine.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole.	Approved
Sulfisoxazole	The metabolism of Hydromorphone can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sultopride.	Experimental
Suvorexant	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tasimelteon.	Approved, Investigational
Telaprevir	The metabolism of Hydromorphone can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Hydromorphone can be decreased when combined with Telithromycin.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Hydromorphone.	Approved, Investigational
Terbinafine	The metabolism of Hydromorphone can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrabenazine.	Approved, Investigational
Tetracaine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracaine.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrodotoxin.	Investigational
Thalidomide	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theobromine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Theobromine.	Approved, Investigational
Thiamylal	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal.	Approved, Vet Approved
Thiazinam	Thiazinam may increase the hypotensive activities of Hydromorphone.	Experimental
Thiethylperazine	Thiethylperazine may increase the hypotensive activities of Hydromorphone.	Withdrawn
Thiopental	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopental.	Approved, Vet Approved
Thioproperazine	Thioproperazine may increase the hypotensive activities of Hydromorphone.	Approved
Thioridazine	The metabolism of Hydromorphone can be decreased when combined with Thioridazine.	Approved, Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiapride.	Approved, Investigational
Ticagrelor	The metabolism of Hydromorphone can be decreased when combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Hydromorphone can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ticrynafen.	Withdrawn
Tiletamine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tilidine.	Experimental
Tiotropium	The risk or severity of adverse effects can be increased when Tiotropium is combined with Hydromorphone.	Approved
Tipranavir	The metabolism of Hydromorphone can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.	Approved, Investigational
Tocilizumab	The serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab.	Approved
Tolbutamide	The metabolism of Hydromorphone can be decreased when combined with Tolbutamide.	Approved, Investigational
Tolcapone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone.	Approved, Withdrawn
Toloxatone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Toloxatone.	Approved
Tolterodine	The risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone.	Approved, Investigational
Tolvaptan	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolvaptan.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Topiramate.	Approved
Topiroxostat	The metabolism of Hydromorphone can be decreased when combined with Topiroxostat.	Approved, Investigational
Torasemide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone.	Approved, Investigational
Tranylcypromine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tranylcypromine.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trazodone.	Approved, Investigational
Triamterene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tricaine methanesulfonate.	Vet Approved
Trichlormethiazide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide.	Approved, Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichloroethylene.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine.	Approved, Vet Approved
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydromorphone.	Approved
Trimethaphan	The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone.	Approved, Investigational
Trimethoprim	The metabolism of Hydromorphone can be decreased when combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine.	Approved
Tropatepine	The risk or severity of adverse effects can be increased when Tropatepine is combined with Hydromorphone.	Experimental
Tropicamide	The risk or severity of adverse effects can be increased when Tropicamide is combined with Hydromorphone.	Approved, Investigational
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Hydromorphone.	Approved
Tubocurarine	The risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone.	Approved
Ularitide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ularitide.	Investigational
Umeclidinium	The risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydromorphone.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Valproic Acid.	Approved, Investigational
Valsartan	The metabolism of Hydromorphone can be decreased when combined with Valsartan.	Approved, Investigational
Vecuronium	The risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.	Approved
Vemurafenib	The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydromorphone.	Approved
Venlafaxine	The metabolism of Hydromorphone can be decreased when combined with Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Veralipride.	Experimental
Verapamil	The metabolism of Hydromorphone can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vigabatrin.	Approved
Vinyl ether	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vinyl ether.	Experimental
Voriconazole	The metabolism of Hydromorphone can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vortioxetine.	Approved, Investigational
Xenon	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Xenon.	Experimental
Xipamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Xipamide.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Xylazine.	Vet Approved
Zafirlukast	The metabolism of Hydromorphone can be decreased when combined with Zafirlukast.	Approved, Investigational
Zaleplon	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide.	Approved
Zimelidine	Hydromorphone may increase the serotonergic activities of Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Hydromorphone can be decreased when combined with Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zolazepam.	Vet Approved
Zolpidem	Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

• Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, "Morphinone reductase for the preparation of hydromorphone and hydrocodone." U.S. Patent US5571685, issued November, 1990.

US5571685

General References

1. Coda BA, Rudy AC, Archer SM, Wermeling DP: Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003 Jul;97(1):117-23, table of contents. [PubMed:12818953]
2. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981 Apr;21(4):152-6. [PubMed:6165742]

External Links

Human Metabolome Database

HMDB0014472

KEGG Compound

C07042

PubChem Compound

5284570

PubChem Substance

46508700

ChemSpider

4447624

BindingDB

50241341

ChEBI

5790

ChEMBL

CHEMBL398707

Therapeutic Targets Database

DAP000472

PharmGKB

PA449918

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Hydromorphone

ATC Codes

N02AG04 — Hydromorphone and antispasmodics

• N02AG — Opioids in combination with antispasmodics
• N02A — OPIOIDS
• N02 — ANALGESICS
• N — NERVOUS SYSTEM

N02AA03 — Hydromorphone

• N02AA — Natural opium alkaloids
• N02A — OPIOIDS
• N02 — ANALGESICS
• N — NERVOUS SYSTEM

AHFS Codes

• 28:08.08 — Opiate Agonists

FDA label

Download (78.9 KB)

MSDS

Download (48.3 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Recruiting	Treatment	Lumbar Spinal Instability / Lumbar Spine Degeneration / Spinal Stenosis of Lumbar Region	1
0	Recruiting	Treatment	Pain	1
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Not Available	Heroin Dependence / Opioid-Related Disorders	1
1	Completed	Treatment	Addictions / Opioid Dependence / Pain	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Opioid-Related Disorders / Pain, Chronic	1
1	Completed	Treatment	Pain	1
1, 2	Completed	Treatment	Opioid Abuse / Opioid Addiction / Stimulant Abuse / Stimulant Addiction	1
1, 2	Terminated	Treatment	Wound Healing	1
2	Active Not Recruiting	Treatment	Adenotonsillitis / Tonsillitis	1
2	Completed	Not Available	Heroin Dependence / Opioid-Related Disorders	1
2	Completed	Treatment	Cesarean Section / Pain	1
2	Completed	Treatment	Labour Pain	1
2	Completed	Treatment	Opiate Dependence	1
2	Completed	Treatment	Opioid Use Disorders	1
2	Completed	Treatment	Postoperative pain	1
2	Not Yet Recruiting	Basic Science	Opioid Abuse / Opioid-use Disorder	1
2	Recruiting	Treatment	Pain	1
2	Withdrawn	Treatment	Hb-SS Disease With Vasoocclusive Pain / Hemoglobin SS Disease With Crisis / Hemoglobin SS Disease With Vasoocclusive Crisis / Other Sickle Cell Disease With Vaso-Occlusive Pain / Sickle Cell Disorders	1
2, 3	Completed	Supportive Care	Chronic Obstructive Pulmonary Disease (COPD)	1
3	Completed	Supportive Care	Management of Chronic Pain	1
3	Completed	Supportive Care	Pain / Prostate Cancer	1
3	Completed	Treatment	Heroin Dependence / Opioid Dependence	1
3	Completed	Treatment	Pain	2
3	Completed	Treatment	Pain, Acute	1
3	Completed	Treatment	Pain, Chronic	1
3	Not Yet Recruiting	Treatment	Pain, Cancer	1
3	Recruiting	Supportive Care	Breast - Female	1
3	Recruiting	Supportive Care	Intraoperative Complications / Malignant Female Reproductive System Neoplasm / Pain	1
3	Recruiting	Treatment	Diseases of Liver	1
3	Recruiting	Treatment	Pain, Chronic	1
3	Terminated	Treatment	Back Pain / Lumbar Spine Fusion / Pain	1
3	Terminated	Treatment	Chronic Non-Malignant Pain	1
3	Terminated	Treatment	Fracture Bone / Pain, Acute / Trauma, Multiple	1
3	Unknown Status	Supportive Care	Cancers / Pain	1
3	Unknown Status	Treatment	Breakthrough Cancer Pain	1
3	Withdrawn	Treatment	Mucositis	1
4	Active Not Recruiting	Treatment	Acute Postoperative Pain / Chronic Persistent Surgical Pain / Hydromorphone Use / Patients Satisfaction	1
4	Active Not Recruiting	Treatment	Analgesia, Obstetrical	1
4	Active Not Recruiting	Treatment	Postoperative pain	1
4	Completed	Basic Science	Healthy Volunteers	1
4	Completed	Supportive Care	Sickle Cell Disorders	1
4	Completed	Treatment	Acute Postoperative Pain	1
4	Completed	Treatment	Analgesia, Obstetrical / Cesarean Section	1
4	Completed	Treatment	Labour Pain	1
4	Completed	Treatment	Low Back Pain (LBP)	1
4	Completed	Treatment	Migraines	1
4	Completed	Treatment	Narcotic Use / Nausea / Occasional Constipation / Pain	1
4	Completed	Treatment	Nausea	1
4	Completed	Treatment	Pain	3
4	Completed	Treatment	Pain, Acute	3
4	Completed	Treatment	Pain, Cancer	1
4	Completed	Treatment	Pain, Neuropathic	1
4	Completed	Treatment	Post Operative Pain	1
4	Completed	Treatment	Postoperative pain	2
4	Completed	Treatment	Unilateral Knee Arthroplasty	1
4	Not Yet Recruiting	Treatment	Analgesics, Opioid / Anti-Inflammatory Agents, Non-Steroidal / Child/Adolescent Problems / Emergency Service, Hospital / Fentanyl / Ibuprofen / Pain, Acute	1
4	Not Yet Recruiting	Treatment	Postoperative pain	1
4	Recruiting	Prevention	Caesarean Sections	1
4	Recruiting	Prevention	Pain / Rotator Cuff Injury	1
4	Recruiting	Supportive Care	Advanced Cancers / Pain	1
4	Recruiting	Supportive Care	Colon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm	1
4	Recruiting	Treatment	Abdominal Pain (AP)	1
4	Recruiting	Treatment	BMI >30 kg/m2 / Postoperative pain / Respiratory Insufficiency	1
4	Recruiting	Treatment	Body Weight Changes / Postoperative Hemorrhages / Postoperative pain / Prophylaxis against postoperative nausea and vomiting	1
4	Recruiting	Treatment	Breakthrough Pain / Pain, Chronic / Pain, Intractable	1
4	Recruiting	Treatment	Fusion of Spine, Lumbar Region	1
4	Recruiting	Treatment	Pain	1
4	Recruiting	Treatment	Pain, Acute	1
4	Recruiting	Treatment	Pectus Excavatum	1
4	Terminated	Treatment	Pain	1
4	Unknown Status	Not Available	Adults / Healthy Volunteers / Humans / Parturient	1
4	Unknown Status	Treatment	Acute Severe Pain	1
4	Unknown Status	Treatment	Pain	2
4	Unknown Status	Treatment	Pain, Acute	1
4	Withdrawn	Treatment	Pain, Acute / Postoperative pain / Surgery, Colorectal	1
Not Available	Active Not Recruiting	Treatment	Rib Fractures	1
Not Available	Completed	Not Available	Breakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors	1
Not Available	Completed	Not Available	Cancer of the Ovary / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Pain / Perioperative/Postoperative Complications / Sarcomas	1
Not Available	Completed	Not Available	General Surgery	1
Not Available	Completed	Prevention	Prophylaxis against postoperative nausea and vomiting	1
Not Available	Completed	Supportive Care	Pain Measurement / Visual Analog Pain Scale	1
Not Available	Completed	Treatment	Analgesia, Obstetrical / Obstetric Surgical Procedures	1
Not Available	Completed	Treatment	Cancer, Breast	1
Not Available	Completed	Treatment	Conditions Requiring Colorectal Surgery	1
Not Available	Completed	Treatment	Low Back Pain (LBP)	1
Not Available	Completed	Treatment	Opioid-Related Disorders	1
Not Available	Completed	Treatment	Post Operative Pain	1
Not Available	Completed	Treatment	Lumbar epidural anesthesia	1
Not Available	Enrolling by Invitation	Basic Science	Healthy Volunteers	1
Not Available	Not Yet Recruiting	Not Available	Anaesthesia therapy / Pain	1
Not Available	Not Yet Recruiting	Prevention	Caudal epidural block therapy / Postoperative pain / Surgery, Cardiac	1
Not Available	Recruiting	Not Available	Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal	1
Not Available	Recruiting	Prevention	Postoperative pain	1
Not Available	Recruiting	Prevention	Pregnancy	1
Not Available	Recruiting	Treatment	Nausea / Pain	1
Not Available	Recruiting	Treatment	Pain / Post Operative Nausea and Vomiting (PONV)	1
Not Available	Terminated	Supportive Care	Pain / Respiratory Depression	1
Not Available	Terminated	Treatment	Laparoscopic Colorectal Resection	1
Not Available	Unknown Status	Treatment	Pain	1
Not Available	Withdrawn	Treatment	Pain / Ventilatory Depression	1

Pharmacoeconomics

Manufacturers

• Purdue pharma lp
• Purdue pharmaceutical products lp
• Akorn inc
• Barr laboratories inc
• Hospira inc
• Watson laboratories inc
• Roxane laboratories inc
• Mallinckrodt inc
• Actavis totowa llc
• Kv pharmaceutical co
• Lannett holdings inc
• Tyco healthcare mallinckrodt

Packagers

• Abbott Laboratories Ltd.
• Akorn Inc.
• Barr Pharmaceuticals
• BASF Corp.
• Baxter International Inc.
• Blenheim Pharmacal
• Bristol-Myers Squibb Co.
• Cardinal Health
• D.M. Graham Laboratories Inc.
• Direct Dispensing Inc.
• Endo Pharmaceuticals Inc.
• Ethex Corp.
• Hospira Inc.
• KV Pharmaceutical Co.
• Lake Erie Medical and Surgical Supply
• Lannett Co. Inc.
• Mallinckrodt Inc.
• Mckesson Corp.
• Nucare Pharmaceuticals Inc.
• Paddock Labs
• PD-Rx Pharmaceuticals Inc.
• Pharmakon
• Pharmedium
• Physicians Total Care Inc.
• Purdue Pharma LP
• Qualitest
• Rhodes Pharmaceutical LP
• Roxane Labs
• Stat Rx Usa

Dosage forms

Form	Route	Strength
Capsule, extended release	Oral	9 mg
Injection, solution	Intramuscular; Intravenous; Subcutaneous	1 mg/mL
Injection, solution	Intramuscular; Intravenous; Subcutaneous	2 mg/mL
Injection, solution	Intramuscular; Intravenous; Subcutaneous	4 mg/mL
Liquid	Intramuscular; Intravenous; Subcutaneous	2 mg
Liquid	Oral	1 mg
Liquid	Oral	5 mg/5mL
Powder, for solution	Intramuscular; Intravenous; Subcutaneous	250 mg
Tablet	Oral	2 mg/1
Tablet	Oral	4 mg/1
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous; Subcutaneous	10 mg/mL
Injection, solution	Intramuscular; Intravenous; Subcutaneous	10 mg/mL
Liquid	Intramuscular; Intravenous; Subcutaneous	10 mg
Liquid	Intramuscular; Intravenous; Subcutaneous	50 mg
Tablet, extended release	Oral	12 mg/1
Tablet, extended release	Oral	16 mg/1
Tablet, extended release	Oral	8 mg/1
Capsule, extended release	Oral	4.5 mg
Capsule, extended release	Oral	9.0 mg
Capsule, extended release	Oral	12 mg
Capsule, extended release	Oral	18 mg
Capsule, extended release	Oral	24 mg
Capsule, extended release	Oral	30 mg
Capsule, extended release	Oral	3 mg
Capsule, extended release	Oral	6 mg
Injection, solution	Intramuscular; Intravenous; Subcutaneous	.5 mg/mL
Injection, solution	Intravenous	.1 mg/mL
Injection, solution	Intravenous	.2 mg/mL
Injection, solution	Intravenous	.4 mg/mL
Injection, solution	Intravenous	1 mg/mL
Injection, solution	Intravenous	10 mg/mL
Injection, solution	Intravenous	2 mg/mL
Solution	Intramuscular; Intravenous; Subcutaneous	10 mg
Solution	Intramuscular; Intravenous; Subcutaneous	20 mg
Solution	Intramuscular; Intravenous; Subcutaneous	50 mg
Solution	Intramuscular; Intravenous; Subcutaneous	1000 mg
Injection	Intramuscular; Intravenous; Subcutaneous	2 mg/mL
Injection	Parenteral	10 mg/mL
Solution	Oral	1 mg/mL
Solution	Oral	5 mg/5mL
Suppository	Rectal	3 mg/1
Tablet	Oral	8 mg/1
Tablet, extended release	Oral	32 mg/1
Tablet, film coated	Oral	2 mg/1
Tablet, film coated	Oral	4 mg/1
Tablet, film coated	Oral	8 mg/1
Tablet, film coated, extended release	Oral	12 mg/1
Tablet, film coated, extended release	Oral	16 mg/1
Tablet, film coated, extended release	Oral	8 mg/1
Solution	Intramuscular; Intravenous; Subcutaneous	100 mg
Solution	Intramuscular; Intravenous; Subcutaneous	2 mg
Tablet, extended release	Oral	16 mg
Tablet, extended release	Oral	32 mg
Tablet, extended release	Oral	4 mg
Tablet, extended release	Oral	8 mg
Capsule, extended release	Oral	16 mg
Syrup	Oral	1 mg
Suppository	Rectal	3 mg
Tablet	Oral	1 mg
Tablet	Oral	2 mg
Tablet	Oral	4 mg
Tablet	Oral	8 mg

Prices

Unit description	Cost	Unit
Hydromorphone hcl powder	166.25USD	g
Dilaudid-hp 250 mg vial	114.8USD	vial
Dilaudid Sterile Powder 250 mg/vial	78.99USD	vial
HYDROmorphone HCl 6 3 mg Suppository Box	54.92USD	box
Hydromorphone Hp 50 50 mg/ml	13.78USD	ml
Dilaudid-Xp 50 mg/ml	11.82USD	ml
Hydromorphone 3 mg suppository	11.11USD	suppository
Dilaudid-Hp-Plus 20 mg/ml	5.08USD	ml
Hydromorphone Hp 20 20 mg/ml	4.72USD	ml
Hydromorph Contin 30 mg Controlled-Release Capsule	4.21USD	capsule
Hydromorph Contin 24 mg Controlled-Release Capsule	3.52USD	capsule
Dilaudid-Hp 10 mg/ml	3.14USD	ml
Hydromorphone Hp 10 mg/ml	2.92USD	ml
Hydromorph Contin 18 mg Controlled-Release Capsule	2.75USD	capsule
Hydromorphone 10 mg/ml ampul	2.58USD	ml
Pms-Hydromorphone 3 mg Suppository	2.42USD	suppository
Dilaudid 4 mg/ml ampul	2.2USD	ml
Dilaudid 8 mg tablet	2.19USD	tablet
HYDROmorphone HCl 4 mg/ml Solution 1ml Cartridge	2.07USD	cartridge
Hydromorph Contin 12 mg Controlled-Release Capsule	1.91USD	capsule
Dilaudid 2 mg/ml ampul	1.81USD	ml
Dilaudid 1 mg/ml ampul	1.64USD	ml
Hydromorphone hcl 8 mg tablet	1.4USD	tablet
Dilaudid 4 mg tablet	1.36USD	tablet
Hydromorphone 8 mg tablet	1.32USD	tablet
Dilaudid 2 mg/ml	1.28USD	ml
Hydromorphone 2 mg/ml	1.19USD	ml
Hydromorph Contin 6 mg Controlled-Release Capsule	1.1USD	capsule
Hydromorphone-ns 0.4 mg/ml	1.08USD	ml
Hydromorphone-ns 0.3 mg/ ml	1.05USD	ml
Hydromorphone 2 mg/ml vial	1.02USD	ml
Hydromorphone-ns 25 mg/25 ml	1.01USD	ml
Dilaudid 2 mg tablet	1.0USD	tablet
Hydromorphone-ns 2.5 mg/25 ml	0.96USD	ml
HYDROmorphone HCl 4 mg tablet	0.8USD	tablet
HYDROmorphone HCl 2 mg tablet	0.77USD	tablet
Hydromorph Contin 3 mg Controlled-Release Capsule	0.73USD	capsule
Hydromorphone 4 mg tablet	0.72USD	tablet
Dilaudid 8 mg Tablet	0.55USD	tablet
Hydromorphone-ns 0.2 mg/ml	0.49USD	ml
Hydromorphone 2 mg tablet	0.37USD	tablet
Pms-Hydromorphone 8 mg Tablet	0.37USD	tablet
Dilaudid 4 mg Tablet	0.35USD	tablet
Dilaudid-5 1 mg/ml liquid	0.33USD	ml
Hydromorphone-ns 5.5 mg/55 ml	0.33USD	ml
Dilaudid 2 mg Tablet	0.23USD	tablet
Pms-Hydromorphone 4 mg Tablet	0.23USD	tablet
Dilaudid 1 mg Tablet	0.16USD	tablet
Pms-Hydromorphone 2 mg Tablet	0.15USD	tablet
Pms-Hydromorphone 1 mg Tablet	0.1USD	tablet
Dilaudid 1 mg/ml Liquid	0.09USD	ml
Pms-Hydromorphone 1 mg/ml Liquid	0.07USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5968551	No	1994-12-24	2011-12-24
US6589960	No	2000-11-09	2020-11-09
US9248229	No	2014-03-12	2034-03-12
US9731082	No	2012-04-23	2032-04-23

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	266.5 °C	PhysProp
logP	0.9	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	4.39 mg/mL	ALOGPS
logP	1.69	ALOGPS
logP	1.62	ChemAxon
logS	-1.8	ALOGPS
pKa (Strongest Acidic)	10.11	ChemAxon
pKa (Strongest Basic)	8.59	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	49.77 Å2	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	78.26 m3·mol-1	ChemAxon
Polarizability	30.02 Å3	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9931
Caco-2 permeable	+	0.8647
P-glycoprotein substrate	Substrate	0.8174
P-glycoprotein inhibitor I	Non-inhibitor	0.8497
P-glycoprotein inhibitor II	Non-inhibitor	0.9641
Renal organic cation transporter	Inhibitor	0.6374
CYP450 2C9 substrate	Non-substrate	0.7925
CYP450 2D6 substrate	Substrate	0.8618
CYP450 3A4 substrate	Substrate	0.7571
CYP450 1A2 substrate	Non-inhibitor	0.6918
CYP450 2C9 inhibitor	Non-inhibitor	0.9539
CYP450 2D6 inhibitor	Non-inhibitor	0.5197
CYP450 2C19 inhibitor	Non-inhibitor	0.8088
CYP450 3A4 inhibitor	Non-inhibitor	0.8177
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9413
Ames test	Non AMES toxic	0.7214
Carcinogenicity	Non-carcinogens	0.9554
Biodegradation	Not ready biodegradable	0.9815
Rat acute toxicity	2.9191 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8906
hERG inhibition (predictor II)	Non-inhibitor	0.8992

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Mass Spectrum (Electron Ionization)	MS	splash10-002r-6960000000-9f3d9b17d56e032d76c5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.

Kingdom

Organic compounds

Super Class

Alkaloids and derivatives

Class

Morphinans

Sub Class

Not Available

Direct Parent

Morphinans

Alternative Parents

Phenanthrenes and derivatives / Isoquinolones and derivatives / Tetralins / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / KetonesOxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives

show 5 more

Substituents

Morphinan / Phenanthrene / Isoquinolone / Tetralin / Coumaran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / BenzenoidKetone / Tertiary amine / Tertiary aliphatic amine / Oxacycle / Ether / Azacycle / Organoheterocyclic compound / Amine / Hydrocarbon derivative / Organic oxide / Organooxygen compound / Organonitrogen compound / Organopnictogen compound / Organic nitrogen compound / Organic oxygen compound / Carbonyl group / Aromatic heteropolycyclic compound

show 17 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

morphinane alkaloid, organic heteropentacyclic compound (CHEBI:5790)

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 22:58